Safety and efficacy of collagen crosslinking for the treatment of keratoconus
- 4 June 2010
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 9 (6), 949-957
- https://doi.org/10.1517/14740338.2010.495117
Abstract
Keratoconus is a condition that causes corneal ectasia and reduced vision in young adults. A proportion of these patients have progressive disease requiring corneal transplantation. A revolutionary new treatment that is purported to halt progression of keratoconus, known as collagen crosslinking (CXL), has recently been introduced into clinical practice. CXL involves the treatment of the cornea with riboflavin followed by photoactivation with UVA light leading to corneal strengthening. This article reviews the basic science, clinical protocols, safety aspects and clinical results of CXL. The reader will gain a comprehensive understanding of: i) the basic science of CXL; ii) the optimised protocols for clinical use of CXL; iii) the results of all the main clinical trials in the literature; iv) contraindications to treatment and v) full clinical safety profile of CXL. CXL represents a new treatment that uniquely allows the halt of progression of keratoconus, thus preventing visual loss and the need for surgical intervention. Available data suggest that this treatment has high efficacy and is very safe and may represent the future standard treatment for progressive keratoconus.Keywords
This publication has 39 references indexed in Scilit:
- Long-term Results of Riboflavin Ultraviolet A Corneal Collagen Cross-linking for Keratoconus in Italy: The Siena Eye Cross StudyAmerican Journal of Ophthalmology, 2010
- Smoking and Corneal BiomechanicsOphthalmology, 2009
- Complication and failure rates after corneal crosslinkingJournal of Cataract & Refractive Surgery, 2009
- Corneal Collagen Cross-Linking: A Confocal, Electron, and Light Microscopy Study of Eye Bank CorneasCornea, 2009
- Biomechanical evidence of the distribution of cross-links in corneastreated with riboflavin and ultraviolet A lightJournal of Cataract & Refractive Surgery, 2006
- Thermomechanical Behavior of Collagen-Cross-Linked Porcine CorneaOphthalmologica, 2004
- Keratocyte cytotoxicity of riboflavin/UVA-treatment in vitroEye, 2004
- Increased resistance of crosslinked cornea against enzymatic digestionCurrent Eye Research, 2004
- AGGREGATION OF COLLAGEN EXPOSED TO UVA IN THE PRESENCE OF RIBOFLAVIN: A PLAUSIBLE ROLE OF TYROSINE MODIFICATIONPhotochemistry and Photobiology, 1994
- The Cross-Linking and Structure Modification of the Collagen Matrix in the Design of Cardiovascular ProsthesisJournal of Cardiac Surgery, 1988